Expert in operating room smoke and abdominal pressure management: Precision surgery's ideal assistant - Changzhou Henghe Angel Financing Plan

I. Industry Development and Existing Pain Points

Henghe Medical Technology (Changzhou) Co., Ltd. was founded in August 2024 and is located in the China-Israel Entrepreneurship Industrial Park in Wujin District, Changzhou. It is an innovative medical device enterprise focused on fluid equipment, instruments, and consumables for surgical operating rooms. The company has received seed round investment from XBOTPARK led by Professor Li Zexiang of the Hong Kong University of Science and Technology. It deeply integrates industry-university-research resources, leverages the advantages of the Yangtze River Delta high-end equipment manufacturing industrial cluster, and has established a joint laboratory with Israeli medical technology enterprises to build a full-chain innovation system from conceptual design to mass production. The enterprise is positioned in the field of minimally invasive surgical fluid management, with core products including a circulating constant-pressure smoke evacuation pneumoperitoneum system, specialized trocars, and supporting consumables. It is committed to providing global medical institutions with comprehensive solutions for high-precision pneumoperitoneum machines, intelligent infusion pumps, and matching consumables.

At present, the technological development of pneumoperitoneum machines lags behind, and there are four major clinical pain points:

Unstable Pressure — Traditional pneumoperitoneum machines lack a continuous gas replenishment mechanism, and pressure loss cannot be recovered in time, leading to surgical pauses or operational errors;

Smoke Hazards — Energy-based instruments generate bacteria and virus-laden smoke when cutting tissues. Manual smoke exhaust without treatment endangers the health of medical staff upon inhalation;

Blurred Visual Field — Condensation on the lens and smoke adhesion lead to frequent wiping, prolonging surgical time;

Postoperative Pain — CO₂ absorption causes hypercapnia. The longer the operation time and the higher the pressure, the more severe the patient's pain.

II. Market Size and Core Technological Breakthroughs

Pneumoperitoneum Machine Market: The global fully automatic pneumoperitoneum machine market size was approximately USD 736 million in 2025, and it is expected to reach USD 1.244 billion by 2032, with a compound annual growth rate of 7.9%. Nearly 3,000 tertiary hospitals and nearly 7,000 secondary hospitals in China have fully launched minimally invasive laparoscopic surgeries, with the total number of minimally invasive surgeries reaching no less than 40 million per year, and the installed base of pneumoperitoneum machines is at least 50,000 units.

Trocar Market: In 2022, the market size of single-use trocars in China reached RMB 2.23 billion, with a compound annual growth rate of 19.8% from 2017 to 2022, and it is expected to grow to RMB 6.3 billion by 2025. The intelligent pneumoperitoneum system is used in conjunction with specialized trocars, penetrating the trocar market through the pneumoperitoneum system.

The company's core product, the circulating constant-pressure smoke evacuation pneumoperitoneum system, has achieved breakthroughs in the following aspects:

Constant Pressure Control Technology: Adopting a fuzzy PID control strategy, it only takes 2.2 seconds to restore stable abdominal pressure under 20L/min air leakage conditions, far outperforming traditional products;

Intelligent Fluid Control: Achieves a flow variation detection accuracy of 0.5L/min, and a multi-stage gas capacity and resistance network eliminates airflow jitter;

Efficient Filtering and Circulating Smoke Evacuation: Bacteria-level filtration, closed-loop management of surgical smoke with no odor escape, reducing lens wiping frequency;

Multi-Parameter Real-Time Monitoring: Intelligent regulation of pressure, temperature, and humidity to maintain stable abdominal pressure and reduce patient side effects;

Surgical Robot AI Interconnection: Integrates the pneumoperitoneum machine into the main system of the surgical robot, where the operating parameters and functions of the pneumoperitoneum machine are interconnected with the settings of the surgical robot, forming a coordinated intelligent AI-driven control unit.

III. Clear Business Model and Market Entry in Progress

The company adopts a model of "technology R&D as the foundation, equipment + consumables sales as the leading force":

R&D End: Continuously iterating equipment performance to enhance clinical recognition

Production End: Optimizing the supply chain, strictly controlling quality, and building a self-owned brand

Sales End: Simultaneously developing OEM manufacturing and self-owned brand operations. 150 units will be delivered to signed OEM customers within the year, and 6 sets have been sold overseas

Profit Path: Generating revenue through veterinary market sales in the short term; obtaining income by providing technical cooperation and registration services in the medium term; fully entering the end market after completing Class II medical device registration in the long term. Sales have already started in some overseas markets.

The company has completed the XBOTPARK seed round investment under Professor Li Zexiang, and is now launching a new round of financing with a target amount of RMB 8 million. The funds will be used for:

1. Mass Production and Regulatory Approval — Completing mass production of the circulating constant-pressure smoke evacuation pneumoperitoneum system, passing product registration testing, and ensuring the quality system meets medical device production requirements;

2. New Product Development — Completing follow-up R&D planning for constant-pressure infusion pumps and specialized consumables.

3. Building a Complete Team — Establishing the production and quality management team, while expanding the R&D team to accommodate more projects.

Minimally invasive surgery has become the core direction of modern surgical development. As an indispensable basic device for laparoscopic surgery, the technological upgrade of pneumoperitoneum machines is directly related to surgical quality, patient prognosis, and the occupational health of medical staff. Currently, the domestic substitution rate in China's pneumoperitoneum machine market is only 10%, with imported brands long dominating the high-end market. Product functions lag behind actual clinical needs, and the clearly defined pain points have not been effectively resolved for a long time.

Henghe Medical seizes this structural opportunity, relying on the industry-university-research resources led by Professor Li Zexiang and the advantages of the Yangtze River Delta high-end manufacturing industrial chain. Taking self-developed core technologies such as constant pressure control, intelligent fluid management, and efficient circulating filtration as breakthrough points, the company has launched a globally competitive circulating constant-pressure smoke evacuation pneumoperitoneum system. The product has achieved full benchmarking and surpassing of imported competing products in key performance indicators such as pressure stability, smoke evacuation efficiency, and filtration level, with core invention patents entering the substantive examination stage and clear differentiated advantages.

The company adopts a sustainable profit model of "equipment + specialized consumables", has obtained OEM customer orders and realized overseas sales, with the commercialization process steadily advancing. With the support of financing, Henghe Medical will accelerate product registration, mass production, and pipeline expansion, striving to achieve a 30% domestic market share of pneumoperitoneum machines within 3 to 6 years and become a benchmark enterprise for minimally invasive surgical fluid management covering all scenarios of rigid and soft endoscopes.

The technological upgrade of minimally invasive surgical fluid management is not only an important direction for domestic medical devices to achieve import substitution, but also a practical need to improve surgical efficiency and protect the health of doctors and patients. Henghe Medical is committed to continuously deepening its efforts in this niche field, providing better clinical solutions through solid technological accumulation and a clear commercial path, and creating long-term and stable value returns for investors.